Pediatric perampanel poisoning

Perampanel is an anticonvulsant that was initially approved in 2012 as adjunct therapy for patients 12  years and older with partial-onset seizures with or without secondarily generalized seizures [1]. It has since been approved as monotherapy for partial onset seizures and its use expanded to include pediatric patients 4 years and older [2]. It is a non-competitive alpha-amino-3-hydroxy-5-methyl -4-isoxazolepropionic acid (AMPA) glutamate receptor antagonist [1]. Currently, the published overdose information available involves only adults [3-7].
Source: The American Journal of Emergency Medicine - Category: Emergency Medicine Authors: Source Type: research